Kenvue to Announce Second Quarter 2025 Results on August 7, 2025
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event.
About Kenvue
Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a minute ago
- Globe and Mail
Fiserv, Inc. (FI) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Fiserv, Inc. ('Fiserv' or the 'Company') (NYSE: FI) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FISERV, INC. (FI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On April 24, 2025, Fiserv reported that the gross payment volume ('GPV') of its merchant payment gateway, Clover, had only seen a growth of 8% for the first quarter of 2025, compared to 14% to 17% from the previous year. The Company attributed the slowing growth to lower 2025 transaction volumes from merchants using the older payment gateway, Payeezy, who had converted to Clover. On this news, Fiserv's stock price fell $40.20, or 18.5%, to close at $176.90 per share on April 24, 2025, thereby injuring investors. Then, on May 15, 2025, Fiserv disclosed that GPV growth deceleration would continue throughout 2025. On this news, Fiserv's stock price fell $30.73, or 16.2%, to close at $159.13 per share on May 15, 2025. Then, on July 23, 2025, Fiserv lowered the top end of its full-year organic growth guidance range and confirmed that its quarterly organic revenue in the Merchant segment had decelerated to 9% year-over-year from 11% in the previous quarter. On this news, Fiserv's stock price fell $22.98, or 13.8%, to close at $143.00 per share on July 23, 2025, thereby injuring investors further.
Toronto Star
43 minutes ago
- Toronto Star
Latin Metals Expands Organullo Gold Project, Salta Province, Argentina
VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) — Latin Metals Inc. ('Latin Metals' or the 'Company') (TSXV: LMS) (OTCQB: LMSQF) is pleased to report that following an application submitted to the mining authorities in Salta Province, the Company has secured rights to the 1,032-hectare Malena VI mining property (the 'Malena VI') (Figure 1). Malena VI is contiguous with the existing Organullo gold project and will form part of the properties included in an existing option agreement (the 'Option') with AngloGold Argentina Exploraciones S.A. ('AngloGold Ashanti'), a wholly owned subsidiary of AngloGold Ashanti plc. (NYSE: AU) under the terms of which AngloGold Ashanti has an option to earn up to an 80% interest in the Company's Organullo, Ana Maria, and Trigal Gold projects. Figure 1: Location of newly acquired Malena VI property relative to the existing Organullo Gold Project. Background image is Total Magnetic Intensity (reduced to pole). 'This acquisition provides a meaningful addition to the Organullo gold exploration project, extending the prospective northeast-southwest structural corridor by nearly 4km toward the southwest,' stated Keith Henderson, Latin Metals' President & CEO. 'This expansion opens new opportunities for additional target generation in close proximity to already-established targets.' ARTICLE CONTINUES BELOW Qualified Person Eduardo Leon, QP, is the Company's qualified person as defined by NI 43-101 and has reviewed the scientific and technical information that forms the basis for portions of this news release. He has approved the disclosure herein. Mr. Leon is not independent of the Company, as he is an employee of the Company and holds securities of the Company. About Latin Metals Latin Metals Inc. is a copper, gold and silver exploration company operating in Peru and Argentina under a prospect generator model, minimizing risk and dilution while maximizing discovery potential. With 18 projects, the company secures option agreements with major mining companies to fund exploration. This approach provides early-stage exposure to high-value mineral assets. Stay Connected Follow Latin Metals on YouTube, X, Facebook, LinkedIn and Instagram to stay informed on our latest developments, exploration updates, and corporate news. On Behalf of the Board of Directors of LATIN METALS INC. 'Keith Henderson' President & CEO For further details on the Company, readers are referred to the Company's website ( and its Canadian regulatory filings on SEDAR+ at For further information, please contact: Keith Henderson Suite 890 – 999 West Hastings Street, Vancouver, BC, V6C 2W2 Phone: 604-638-3456 E-mail: info@ Elyssia Patterson, VP Investor Relations Email: elyssia@ Phone: 778-683-4324 Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements and forward-looking information (collectively, 'forward-looking statements') within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, the anticipated content, commencement, timing and cost of exploration programs in respect of the Property and otherwise, anticipated exploration program results from exploration activities, and the Company's expectation that it will be able to enter into agreements to acquire interests in additional mineral properties, the discovery and delineation of mineral deposits/resources/reserves on the Properties, and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward looking information can be identified by words such as 'pro forma', 'plans', 'expects', 'may', 'should', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'potential' or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, market fundamentals will result in sustained precious and base metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future development of the Company's Argentine projects in a timely manner, the availability of financing on suitable terms for the development, construction and continued operation of the Company projects, and the Company's ability to comply with environmental, health and safety laws. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and other factors include, among others, operating and technical difficulties in connection with mineral exploration and development and mine development activities at the Properties, including the geological mapping, prospecting and sampling programs being proposed for the Properties (the 'Programs'), actual results of exploration activities, including the Programs, estimation or realization of mineral reserves and mineral resources, the timing and amount of estimated future production, costs of production, capital expenditures, the costs and timing of the development of new deposits, the availability of a sufficient supply of water and other materials, requirements for additional capital, future prices of precious metals and copper, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, possible variations in ore grade or recovery rates, possible failures of plants, equipment or processes to operate as anticipated, accidents, labour disputes and other risks of the mining industry, delays or the inability of the Company to obtain any necessary permits, consents or authorizations required, any current or future property acquisitions, financing or other planned activities, changes in laws, regulations and policies affecting mining operations, hedging practices, currency fluctuations, title disputes or claims limitations on insurance coverage and the timing and possible outcome of pending litigation, environmental issues and liabilities, risks related to joint venture operations, and risks related to the integration of acquisitions, as well as those factors discussed under the heading as well as those factors discussed under the heading 'Risk Factors' in the Company's annual management's discussion and analysis and other filings of the Company with the Canadian Securities Authorities, copies of which can be found under the Company's profile on the SEDAR+ website at Readers are cautioned not to place undue reliance on forward looking statements. Except as otherwise required by law, the Company undertakes no obligation to update any of the forward-looking information in this news release or incorporated by reference herein. A photo accompanying this announcement is available at:
Toronto Star
2 hours ago
- Toronto Star
Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy
MARLTON, N.J., July 28, 2025 (GLOBE NEWSWIRE) — Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced two major accomplishments, marking an inflection point in the advancement and accessibility of CCM® Therapy. The company successfully completed enrollment in the INTEGRA-D™ Pivotal Trial. This marks a significant milestone in the journey to introduce the CCM-D® HF System, the world's first device combining Impulse Dynamics®' proprietary CCM® therapy for the treatment of HF symptoms with lifesaving, implantable cardioverter defibrillator (ICD) therapy. The trial's initial results, including 100 percent defibrillation success in the efficacy cohort, were presented as a late-breaking clinical trial at Heart Rhythm 2025 and support a forthcoming PMA submission to the FDA. This milestone advances the potential approval of a first-of-its-kind dual therapy that is designed to address both sudden cardiac death and chronic HF symptoms. The American Medical Association (AMA) granted Category I Current Procedural Terminology (CPT) codes for CCM® Therapy. This designation confirms the procedure is both widely performed and supported by strong clinical evidence. Sponsored by the American College of Cardiology (ACC) and Heart Rhythm Society (HRS), this coding advancement represents a major breakthrough in reimbursement access, establishing CCM® as a mainstream therapeutic option. It streamlines insurance billing and lays the foundation for widespread adoption and coverage in the U.S. market.
